Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2020-08-13 Capital/Financing Update
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Appendix 2A - Exercise of employee options 16 pages 200.1KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities being quoted, and the circumstances of the issue. This form is a regulatory announcement related to capital markets activity, specifically the issuance and quotation of new securities. It is not a financial report, earnings release, or management discussion. It is a formal notification to the exchange about capital changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive filing about capital changes.
2020-08-13 English
Preliminary Final Report 64 pages 956.9KB
Annual Report Classification · 100% confidence The document is dated 13 August 2020 and is addressed to the Australian Securities Exchange. It references an Appendix 4E Preliminary Final Report and the 2020 Directors' Report and Annual Financial Report for the year ended 30 June 2020. The content includes detailed financial statements, directors' reports, remuneration reports, corporate governance, senior management information, and an independent auditor's report. The length is substantial (15,000 characters), and the document contains actual financial data and comprehensive management discussion. This matches the characteristics of an Annual Report (10-K equivalent) rather than a mere announcement or certification. Therefore, the document is classified as an Annual Report (10-K). FY 2020
2020-08-12 English
Lapse of 2019 Performance Rights and Expiry of Options 1
Regulatory Filings Classification · 95% confidence The document is a notice from Pharmaxis Ltd to the Australian Securities Exchange regarding the lapse of 2019 performance rights and expiry of options. It mentions specific securities lapsing and references the 2020 Remuneration Report. The content is an announcement about changes in securities related to remuneration but does not contain detailed remuneration data itself. It is not a full Remuneration Information report (DEF 14A) but rather a notification related to securities and remuneration outcomes. Given the nature of the content, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-08-12 English
Change of Director's Interest Notice - G Phillips 2 pages 148.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including the number of shares and options held before and after the change, nature of the change, and dates. This matches the description of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document is concise and focused solely on director share transactions, with no financial statements or broader company information. Therefore, it fits the 'Director's Dealing' category (DIRS).
2020-08-12 English
Appendix 3G - 2020 Grant of Performance Rights 13 pages 178.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3G form submitted to the ASX, which is a notification of the issue, conversion, or payment up of equity securities. It details the issuance of unquoted employee incentive securities (performance rights) and includes specifics about the number of securities, recipients (key management personnel), and terms of the securities. The document is a regulatory announcement about capital changes, specifically the issuance of securities under an employee incentive scheme. It is not a full financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive information about the securities issued. Therefore, the document fits the category of Share Issue/Capital Change (SHA).
2020-08-12 English
Proposed Issue of Securities to Chief Executive Officer 2 pages 164.8KB
Share Issue/Capital Change Classification · 95% confidence The document is a letter addressed to the Australian Securities Exchange announcing a proposed issue of securities (performance rights) to the Chief Executive Officer under the company's employee incentive scheme. It references shareholder approval to be sought at the upcoming Annual General Meeting and mentions compliance with Listing Rule 3.10.3. The content focuses on the grant of securities and related conditions rather than detailed financial data or full report content. The document length is short (2691 characters) and it is an announcement of a capital issuance event related to employee incentives. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2020-08-12 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.